Atropine (EENT)

Drug class: Antineoplastic Agents

Usage of Atropine (EENT)

Ophthalmologic Examination

Used to produce mydriasis and cycloplegia for refraction (e.g., retina and optic disc examination, measurement of refractive error). However, because of long duration of action relative to that of other anticholinergic agents, atropine is seldom, if ever, used for cycloplegic refraction in adults.

In rare cases, ophthalmic atropine use may be necessary to achieve maximal cycloplegia in pediatric patients, but cyclopentolate is more frequently used.

Ophthalmic Inflammation

Management of acute inflammatory conditions (e.g., iridocyclitis) of the iris and uveal tract (e.g., uveitis).

Amblyopia

Used for cycloplegic effects in the treatment of suppression amblyopia (lazy eye) to reduce the visual acuity of the unaffected eye below that of the amblyopic one and force fixation with the amblyopic eye.

Excess Accommodation and Convergence

Used to treat patients with a functional excess of accommodation and convergence.

Relate drugs

How to use Atropine (EENT)

General

  • Prior to initiation of therapy, estimate the depth of the angle of the anterior chamber to avoid induction of angle-closure glaucoma in susceptible patients.

    • Administration

    Ophthalmic Administration

    Apply topically to eye(s) as an ophthalmic ointment or solution.

    For topical ophthalmic use only. Not for injection.

    Following topical application, apply finger pressure on the lacrimal sac for 2–3 minutes to avoid excessive systemic absorption.

    Avoid contamination of the solution or ointment container.

    Dosage

    Available as atropine sulfate; dosage expressed in terms of the salt.

    In patients with heavily pigmented irides, higher dosages may be required.

    Pediatric Patients

    Cycloplegic Refraction† [off-label] Ophthalmic

    1–2 drops of a 0.5% solution in the eye(s) twice daily has been used for 1–3 days before the procedure, but this preparation no longer is commercially available in the US. No specific pediatric dosage recommendations for 1% ophthalmic solution. (See Pediatric Use under Cautions.)

    Alternatively, apply 0.3 cm of a 1% ointment into the conjunctival sac 3 times daily for 1–3 days before the procedure. (See Pediatric Use under Cautions.)

    Inflammatory Conditions Uveitis† [off-label] Ophthalmic

    1–2 drops of a 0.5% solution into the affected eye(s) up to 3 times daily has been used, but this preparation no longer is commercially available in the US. No specific pediatric dosage recommendations for 1% ophthalmic solution.

    Alternatively, apply 0.3–0.5 cm of a 1% ointment into the conjunctival sac of the affected eye(s) 1–3 times daily.

    Adults

    Mydriasis and Cycloplegia for Refraction Ophthalmic

    1 drop of a 1% solution in the eye(s) 1 hour before the procedure.

    Alternatively, apply 0.3–0.5 cm of a 1% ointment into the conjunctival sac 1–3 times daily. If ointment is used for refraction, apply several hours before procedure.

    Inflammatory Conditions Uveitis Ophthalmic

    1–2 drops of a 1% solution into the affected eye(s) up to 4 times daily, or as directed by a clinician. Alternatively, apply 0.3–0.5 cm of a 1% ointment into the conjunctival sac of the affected eye(s) 1–3 times daily.

    Special Populations

    No special population dosage recommendations at this time.

    Warnings

    Contraindications

  • Known hypersensitivity to atropine or any ingredient in the formulation.
  • Pediatric patients who have previously had a severe systemic reaction to atropine.
  • Known or suspected angle-closure (narrow-angle) glaucoma or tendency toward angle-closure glaucoma.

    • Warnings/Precautions

    Warnings

    Overdosage

    Excessive use in children and patients with a history of susceptibility to belladonna alkaloids may produce systemic manifestations of atropine poisoning (e.g., flushing, skin dryness, rash in children, rapid and irregular pulse, fever, abdominal distention in infants, mental aberration, loss of neuromuscular coordination). If systemic symptoms occur, discontinue the drug and initiate appropriate therapy.

    Specific Populations

    Pregnancy

    Category C.

    Lactation

    Not known whether atropine is distributed into milk. Caution when used in nursing women.

    Pediatric Use

    Safety and efficacy of atropine sulfate 1% ophthalmic solution have not been established in pediatric patients.

    Use with extreme caution, if at all, in infants and small children, and in children with spastic paralysis or brain damage because of increased susceptibility to the systemic effects of the drug in these patients.

    Coma and death have been reported in very young patients.

    Geriatric Use

    No substantial differences in safety or efficacy relative to younger adults.

    Common Adverse Effects

    Elevated IOP. With prolonged administration, local irritation, hyperemia, edema, exudate, follicular conjunctivitis, dermatitis.

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords

    AI Assitant